Resource Library

Results from the HPTN 084 Trial

The HIV Prevention Trials Network (HPTN) hosted a community webinar to discuss the primary results of HPTN 084, a randomized, double-blind controlled trial designed to evaluate the efficacy and safety of long-acting injectable cabotegravir (CAB LA) to prevent the sexual acquisition of HIV in cisgender women in sub-Saharan Africa.

Research

BioPIC Adaptable Product Introduction Framework

This framework is intended to inform stakeholders involved in all stages of product introduction from clinical research to rollout in low- and middle-income countries (LMICs). While the framework focuses on activities to begin in parallel to phase III clinical trials, stakeholders in early product development phases may also want to understand what to expect in…

Community/Advocacy, Demand Creation/Marketing, Financing & Costing, Monitoring & Evaluation, Research, Service Delivery, Supply Chain Management

A Collaborative Approach to HIV Prevention Product Introduction

The HIV prevention product pipeline offers exciting potential to curb HIV incidence. But we know from previous products that translating trial efficacy to population impact is challenging without coordinated effort.

Community/Advocacy

The Years Ahead in Biomedical HIV Prevention Research

This graphic shows the updated status of large-scale prevention trials through 2024.

Community/Advocacy

Pre-Exposure Prophylaxis: An introductory factsheet

This introductory 2-page document defines PrEP, reviews the scientific evidence to date, and outlines key research, regulatory and advocacy issues going forward. This factsheet is part of a series on emerging HIV prevention strategies.

Community/Advocacy

The Future of ARV-Based Prevention and More

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Community/Advocacy

Stakeholder Conversations to Inform Delivery of New HIV Prevention Methods in South Africa

Little is known about what is needed for health care providers to ensure adequate counseling on method choice, referral mechanisms, and supportive follow-up with regards to multiple biomedical HIV prevention methods. The goal of these conversations with stakeholders in South Africa was to gain input on implementation considerations from provider and potential end-user perspectives, as…

Stakeholder conversations to inform delivery of new HIV prevention methods in Zimbabwe

Little is known about what is needed for health care providers to ensure adequate counseling on method choice, referral mechanisms, and supportive follow-up with regards to multiple biomedical HIV prevention methods. The goal of these conversations with stakeholders in Zimbabwe was to gain input on implementation considerations from provider and potential end-user perspectives, as well…

Modelling Impact of Injectable Cabotegravir for PrEP on Drug Resistance

An important consideration in the scale-up of injectable cabotegravir (CAB) for PrEP is the potential for development of Integrase Strand Transfer Inhibitor (INSTI) resistance. To help stakeholders understand this issue further, Professor Andrew Phillips from University College London shared the results of an exercise modelling the impact of the introduction of CAB for PrEP on…

Financing & Costing, Testing

Product Introduction/Implementation Project Planning for Next-Generation PrEP

Early data from clinical trials has indicated that Cabotegravir (CAB) for PrEP is safe and effective. With an accelerated timeline for introduction of CAB for PrEP, AVAC and WHO convened a think tank to strategize about demonstration projects and other planning for product introduction.